Are Asarfi Hospital Ltd latest results good or bad?

3 hours ago
share
Share Via
Asarfi Hospital Ltd's latest Q3 FY26 results are strong, with a net profit of ₹5.42 crores (up 102.24% year-on-year) and revenue of ₹46.10 crores (up 40.16% year-on-year), indicating robust growth and improved operational efficiency, despite a slight sequential revenue decline. Overall, the company's performance is encouraging for investors.
Asarfi Hospital Ltd's latest financial results for Q3 FY26 indicate a strong performance characterized by significant growth in both revenue and net profit. The company reported a net profit of ₹5.42 crores, which reflects a substantial year-on-year increase of 102.24%. Revenue for the same period reached ₹46.10 crores, marking a year-on-year growth of 40.16%. This consistent upward trend in revenue growth has been maintained over the past three quarters, showcasing the company's ability to capture market demand effectively.
The operating margin for Asarfi Hospital stood at 21.93%, the highest in seven quarters, indicating improved operational efficiency. The PAT margin also expanded to 11.76%, up from 8.15% in the previous year, highlighting the company's effective cost management and profitability enhancement strategies. Furthermore, the operating profit (excluding other income) reached ₹10.11 crores, representing a significant increase from previous periods. Despite the positive growth metrics, the company experienced a sequential decline in revenue growth compared to the previous quarter, which may warrant close monitoring. Additionally, employee costs rose significantly due to expansion initiatives, although this increase was managed relative to revenue growth. Overall, Asarfi Hospital's financial results demonstrate a robust operational performance, with a clear trajectory of growth and profitability. The company saw an adjustment in its evaluation following these results, reflecting its ongoing operational advancements and market positioning. Investors and stakeholders may find the company's performance encouraging as it continues to navigate the healthcare landscape in underserved regions.
{{stockdata.stock.stock_name.value}} Live

{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)

{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)


Our weekly and monthly stock recommendations are here
Loading...
{{!sm.blur ? sm.comp_name : ''}}
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Entry Price
Target Price
{{sm.target_price }} ({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News